ÂÜÀòÂÒÂ×

I-Ming Cho has held a variety of roles in the biotechnology and pharmaceutical industries. In 2011, they began as a Postdoctoral Fellow at Academia Sinica, where they studied the role of a novel protein, Puf-A, in germ cell development and embryonic stem cell differentiation in mammalians. In 2013, they became a Researcher at Medigen Biotechnology Corp., where they developed a novel human vaccine platform using virus-like particles. In 2014, they moved to Phalanx Biotech Group as a Senior Researcher, conducting market surveys, designing and quality controlling DNA microarrays. In 2015, they joined EirGenix. Inc. as a Senior Scientist, leading the group for microbial cell line engineering. In 2018, they became a Project Manager at AbGenomics B.V. Taiwan Branch. Currently, they are an Associate Director at AltruBio Inc., managing clinical trials to ensure projects are executed effectively.

I-Ming Cho obtained a Doctor of Philosophy (Ph.D.) in Molecular Genetics and Biochemistry from The Ohio State University between 2004 and 2010.